

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/030074 A3

(51) International Patent Classification:

A61K 31/404 (2006.01) *A61K 31/403* (2006.01)
C07D 209/04 (2006.01) *A61K 31/33* (2006.01)
C07D 209/16 (2006.01) *C07D 209/02* (2006.01)
A61K 31/40 (2006.01)

(21) International Application Number:

PCT/US2024/040667

(22) International Filing Date:

02 August 2024 (02.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/530,671 03 August 2023 (03.08.2023) US
18/368,143 14 September 2023 (14.09.2023) US

(71) Applicant: **GILGAMESH PHARMACEUTICALS, INC.** [US/US]; 113 University Place, Suite 1019, New York, New York 10003 (US).

(72) Inventors: **KRUEGEL, Andrew Carry**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **LEONG, William**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **HE, Yamen**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **MACEACHERN, Lauren**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

17 April 2025 (17.04.2025)

(54) Title: CRYSTALLINE SALTS OF N-ETHYL-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE

(57) Abstract: The present disclosure relates to a crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine salt selected from crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine monophosphate, crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine mono-*p*-tosylate, crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine hemimalate, and crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine monosuccinate, pharmaceutical compositions comprising same, and uses thereof for treating mood disorders.

WO 2025/030074 A3